Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Wu

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Bioorganic & Medicinal Chemistry Letters|January 2, 2010
Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinemTimothy A Blizzard, Helen Chen, Seongkon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2020
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial CancerVicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®Timothy A Blizzard, Helen Chen, Seongkon Kim, et al.
Bioorganic & Medicinal Chemistry Letters|May 5, 2015
Rapid development of two factor IXa inhibitors from hit to leadDann L Parker, Shawn Walsh, Bing Li, et al.
Communications Biology|March 18, 2022
Characterisation of PDGF-BB:PDGFRβ signalling pathways in human brain pericytes: evidence of disruption in Alzheimer's diseaseLeon C D Smyth, Blake Highet, Deidre Jansson, et al.
Journal of Medicinal Chemistry|January 16, 2020
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic SteatohepatitisDonatella Chianelli, Paul V Rucker, Jason Roland, et al.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2015
Development of a novel tricyclic class of potent and selective FIXa inhibitorsDongfang Meng, Patrick Andre, Thomas J Bateman, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Bioorganic & Medicinal Chemistry Letters|January 2, 2010
Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinemTimothy A Blizzard, Helen Chen, Seongkon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2020
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial CancerVicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®Timothy A Blizzard, Helen Chen, Seongkon Kim, et al.
Bioorganic & Medicinal Chemistry Letters|May 5, 2015
Rapid development of two factor IXa inhibitors from hit to leadDann L Parker, Shawn Walsh, Bing Li, et al.
Communications Biology|March 18, 2022
Characterisation of PDGF-BB:PDGFRβ signalling pathways in human brain pericytes: evidence of disruption in Alzheimer's diseaseLeon C D Smyth, Blake Highet, Deidre Jansson, et al.
Journal of Medicinal Chemistry|January 16, 2020
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic SteatohepatitisDonatella Chianelli, Paul V Rucker, Jason Roland, et al.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2015
Development of a novel tricyclic class of potent and selective FIXa inhibitorsDongfang Meng, Patrick Andre, Thomas J Bateman, et al.
Pageof 6